https://brandessenceresearch.com/ Logo

Lung Cancer Therapies Market

Lung Cancer Therapies Market Size, Share & Trends Analysis Report

Lung Cancer Therapies Market By Type (Push Button Lung Cancer, Pressure Activated Lung Cancer, Side Button Lung Cancer), By Treatment (Surgery, Chemotherapy, Radiotherapy, Laser Therapy), Industry Analysis, Trends, And Forecast 2020

Published
Report ID : BMRC 277
Number of pages : 300
Published Date : May 2023
Category : Healthcare
Delivery Timeline : 48 hrs

Lung Cancer Therapies Market: Rising incidences of lung cancer due to increasing number of smokers and increasing pollution due to rapid industrialization are major key factor which drives the Immunotherapy Drug Market.

Lung Cancer Therapies Market  Leading Key Players

Key players operating in the lung cancer therapeutics market are

  • Hoffmann-La Roche AG
  • Bayer
  • Novartis
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Sanofi
  • Celgene
  • AstraZeneca
  • Ventana
  • Genentech
  • Glaxosmith
  • Boehringer Ingelheim
  • Takeda Pharmaceuticals Co. Ltd
  • Ariad Pharmaceuticals
  • Johnson and Johnson
  • Daiichi Sankyo
  • Teva Pharmaceuticals
  • others

Lung Cancer Therapies Market Segmentation

By Types-

  • Push button Lung Cancer
  • Pressure activated Lung Cancer
  • Side button Lung Cancer
  • Others

By End Users-

  • Hospitals
  • Clinics
  • Diagnostics centers
  • Pathology laboratories
  • Home diagnostics
  • Others

By Treatment-

  • Surgery
  • Chemotherapy
  • Radiotherapy
  • Photodynamic therapy (PDT)
  • Laser therapy
  • Others

 Global Lung Cancer Therapies Market Reports –

Lung cancer is the uncontrolled growth of abnormal cells that develop in one or both lungs generally in the cells which passages the air. The abnormal cells do not develop into healthy lung tissue. They divide rapidly and develop the tumors. Mostly smoking the cigarette causes lung cancers.As tumors become bigger in size and more numerous then lung’s ability to provide the bloodstream with oxygen is decreased.Primary lung cancer develops in the lungs and secondary lung cancer starts some other parts of the body, metastasizes, and reaches the lungs. There are different types of cancers and treatment for this is also varies from type to type.Cigarette smoke contains at least 73 known carcinogens.More cigarettes smoking rate per day and the earlier starting of smoking will have greater risk of lung cancer. The Symptoms of Primary Lung Cancer are Coughing, Shortness of breath, Coughing up blood,repeated problems with pneumonia or bronchitis and Swelling of the neck face. The Symptoms of Primary Lung Cancer are Fatigue, Loss of appetite or weight loss, Headache, Bone & joint pain, Bone fractures not related to accidental injury and General weakness.

 Pathologist identifies lung cancer by using a physical exam, imaging technique and by lab tests. Lung Cancer treatment depends on the type, stage, and how progressive it is. Treatments include surgery, chemotherapy, radiation therapy, and targeted therapy. If lung cancer is suspected as a result of a screening procedure (CT, MRI or PET scan), a small piece of tissue from the lung must be examined under a microscope to look for cancer cells called a biopsy.Recently, the FDA approved the first liquid biopsy for lung cancer which utilizes free floating DNA in the bloodstream for analysis.If cancer cells are found in the tissue sample, a genetic test may be performed. Genetic testing also referred as “molecular profiling or mutation profiling”.There are two major types of lung cancer, Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).Drugs Approved for Non-Small Cell Lung Cancer are Abitrexate, Abraxane, Afatinib Dimaleate Afinitor, Alecensa, Bevacizumab, Brigatinib, Carboplatin, Docetaxel,  Erlotinib Hydrochloride,Gilotrif, Iressa, Mustargen, Osimertinib Paclitaxel, Paraplatin, Tarceva, Taxol Taxotere, Tecentriq, Trametinib, Trexall, Vinorelbine Tartrate, Xalkori and Zykadia.

 Drugs Approved for Small Cell Lung Cancer are Abitrexate,Afinitor, Doxorubicin Hydrochloride Etopophos, Etoposide, Etoposide Phosphate, Everolimus, Folex, Hycamtin, Mechlorethamine Hydrochloride, Methotrexate, Mexate, Mustargen, Topotecan Hydrochloride and Trexall.

 Global Lung Cancer Therapies Market is segmented on the basis of Types, End user, Treatment and Geography. Based upon Types,Global Lung Cancer Therapies Market is classified as Push button Lung Cancer, Pressure activated Lung Cancer and Side button Lung Cancer and Others. On the basis of End users Global Lung Cancer Therapies Market is classified into Hospitals, Clinics, Diagnostics centers,Pathology laboratories, Home diagnostics andothers. On the basis of treatment Global lung Cancer Therapies Market is classified into Surgery, Chemotherapy, Radiotherapy, Photodynamic therapy (PDT) and Laser therapy.

 The regions covered in Global Lung Cancer Therapies Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Global Lung Cancer Therapies Market Dynamics –

Rising incidences of lung cancer due to increasing smoking population are major key factors that drive the growth of Global Lung Cancer Therapies Market. The risk of lung cancer is ten timesmore in smokers as compared to non-smokers. Also, launch of premium priced drugs, new innovative radiation therapies like Radiation, Chemotherapy coupled with rising incidences of Non-Small Cell Lung Cancer(NSCLC)are the major driving factors for the Global Lung Cancer Therapies Market. However, generalization of the major drugs might restrict the growth of Global Lung Cancer Therapies Market. Also poor cancer diagnostic facilities in many countries and the adverse effects of chemotherapies like Nausea, vomiting, Diarrhea, Fatigue and Mouth sores are the factors that are likely to restrain the Global Lung Cancer Therapies Market. But the arrival of Nanomedicine to treat lung cancer like Abraxane and the growing approvals in the lung cancer therapeutics market boost the opportunities for the rise in the Lung Cancer Therapies Market

By Regional & Country Analysis

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Sweden
  • Netherland
  • Turkey
  • Switzerland
  • Belgium
  • Rest of Europe

Asia-Pacific

  • South Korea
  • Japan
  • China
  • India
  • Australia
  • Philippines
  • Singapore
  • Malaysia
  • Thailand
  • Indonesia
  • Rest Of APAC

Latin America

  • Mexico
  • Colombia
  • Brazil
  • Argentina
  • Peru
  • Rest of South America

Middle East and Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest Of MEA

 

SUMMARY
VishalSawant
Vishal Sawant
Business Development
vishal@brandessenceresearch.com
+91 8830 254 358
Segmentation
Segments

By Types-

  • Push button Lung Cancer
  • Pressure activated Lung Cancer
  • Side button Lung Cancer
  • Others

By End Users-

  • Hospitals
  • Clinics
  • Diagnostics centers
  • Pathology laboratories
  • Home diagnostics
  • Others

By Treatment-

  • Surgery
  • Chemotherapy
  • Radiotherapy
  • Photodynamic therapy (PDT)
  • Laser therapy
  • Others
Country
Regions and Country

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Sweden
  • Netherlands
  • Turkey
  • Switzerland
  • Belgium
  • Rest of Europe

Asia-Pacific

  • South Korea
  • Japan
  • China
  • India
  • Australia
  • Philippines
  • Singapore
  • Malaysia
  • Thailand
  • Indonesia
  • Rest of APAC

Latin America

  • Mexico
  • Colombia
  • Brazil
  • Argentina
  • Peru
  • Rest of South America

Middle East and Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest of MEA
Company
Key Players
  • Hoffmann-La Roche AG
  • Bayer
  • Novartis
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Sanofi
  • Celgene
  • AstraZeneca
  • Ventana
  • Genentech
  • Glaxosmith
  • Boehringer Ingelheim
  • Takeda Pharmaceuticals Co. Ltd
  • Ariad Pharmaceuticals
  • Johnson and Johnson
  • Daiichi Sankyo
  • Teva Pharmaceuticals
  • others

+44-1173181773

sales@brandessenceresearch.com

We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us hr@brandessenceresearch.com

JOIN US

LONDON OFFICE

BrandEssence® Market Research and Consulting Pvt ltd.

124, City Road, London EC1V 2NX

FOLLOW US

Twitter
Facebook
LinkedIn
Skype
YouTube

CONTACT US

1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE

© Copyright 2024-25 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®

PaymentModes